NCT Number: NCT00225511
Study Evaluating Effexor XR for Major Depression.
Study Evaluating Effexor XR for Major Depression.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–64 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Nagoya, Aichi-ken, Japan
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients diagnosed with major depression based on DSM-IV-TR
- Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" at the baseline.
Exclusion criteria
- Patients with schizophrenia or any other psychotic disorder
- Patients with history or presence of bipolar disorder
Treatment and study plan
Milnacipran
DrugPrimary outcomes
-
Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy.
Secondary outcomes
-
Difference of total score of HAM-D17 between baseline and final-on-therapy.
-
Remission rate of HAM-D17 at the final-on-therapy.
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression
Important dates
- Study start
- 2004
- First posted
- Sep 23, 2005
- Registry last updated
- May 24, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Ganoderma Spores Modulate the Gut-Brain Axis
NCT07524777
Behavior, Behavioral Symptoms
Hangzhou, Zhejiang, China
View Trial DetailsMOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
NCT05220202
Aging, Behavior
Dallas, Texas, United States
View Trial DetailsNeurobiological Investigations of Mindfulness, Depression and Sleep Disturbances in Medical Staffs and Community Elders
NCT07179172
Behavior, Behavioral Symptoms
New Taipei City, Taiwan
View Trial DetailsApproach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)
NCT04426461
Anxiety, Anxiety Disorders
Tulsa, Oklahoma, United States
View Trial Details